Aura Biosciences vs PharmaCyte Biotech
AURA and PMCB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AURA and PMCB compare
Aura Biosciences is the larger company, worth 184 times as much as PharmaCyte Biotech ($789M against $4.3M).
PharmaCyte Biotech scores higher on the StockData Score (7 against 6 for Aura Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AURA | PMCB |
|---|---|---|
| Size and price | ||
| Market cap | $789M | $4.3M |
| Share price | $7.61 | $0.399 |
| Change, 1 year | 37.9% | −54.7% |
| Change, 5 years | −66.2% | −84.7% |
| Beta (5Y) | 1.37 | 0.76 |
| Employees | 113 | 2 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.7× | 0.2× (better) |
| FCF yield | −13.9% | – |
| Growth | ||
| Net income growth (TTM) | – | −163% |
| Profitability | ||
| Return on equity | −61.7% | −48.9% (better) |
| Return on invested capital | −64.7% | −23.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 14.21 | 40.30 (better) |
| Altman Z-score | 10.83 (better) | −3.43 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 9.4% |
| Shareholder yield | 0.00% | 9.4% (better) |
| Ownership | ||
| Held by institutions | 94.8% | 7.1% |
| Held by insiders | 7.4% | 7.1% |
| Insider net buying, 12 months | −$39.8M | $129K (better) |
| Short interest, % of float | 10.9% | 0.51% |
Go deeper
- AURA stock overview
- AURA income statement
- AURA valuation and score
- PMCB stock overview
- PMCB income statement
- PMCB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.